Skip to main content
Skin Health and Disease logoLink to Skin Health and Disease
editorial
. 2022 Jun 6;2(3):e138. doi: 10.1002/ski2.138

Skin cancer special edition

George W M Millington 1,
PMCID: PMC9435450  PMID: 36092263

Skin cancer is an increasing challenge globally. Keratinocyte cancers (basal cell carcinoma ‐BCC and squamous cell carcinoma–cSCC) are the commonest cancers in white populations, with rates increasing worldwide. 1 On average, one in five people in England will develop one of these tumours in their lifetimes. 1 BCC and cSCC are both more common in males than females in England. 1 However, BCC and cSCC are both more common in females than males in England under the age of 50. 1 Melanoma is the 19th most common cancer internationally. 2 The incidence of melanoma has been increasing worldwide over the past 50 years, especially in white populations and people living nearer to the equator. 2 Australia and New Zealand have experienced the greatest incidence of melanoma, then North America, as well as the European countries, between 2013 and 2015. 2 The incidence rates of Merkel cell carcinoma (MCC), an aggressive cutaneous cancer, have tripled from 0.15 cases per 100,000 individuals in 1986 to 0.7 per 100,000 in 2013. 3 MCC is three times more lethal than melanoma. 3 Although much of the research into skin cancer is in white populations (skin types I and II), there is a growing realization of skin cancer problems in skin of colour, 4 Considering all of this, the editorial team of SHD will launch a themed issue early next year on the subject of Cutaneous Oncology. I am extremely grateful to Ewan Langan (Berlin), Oriol Yelamos (Barcelona), Shamir Geller (Tel Aviv) and Selin Tokez (Rotterdam) for agreeing to be guest editors. If you wish to discuss a skin cancer submission with me, or with any of the guest editors, please email shd@bad.org.uk.

AUTHOR CONTRIBUTIONS

George W. M. Millington: Writing – original draft (lead); Writing – review & editing (lead).

CONFLICT OF INTEREST

George W. M. Millington is the Editor in Chief of Skin Health and Disease.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

REFERENCES

  • 1. Kwiatkowska M, Ahmed S, Ardern‐Jones M, Bhatti LA, Bleiker TO, Gavin A, et al. An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013–2018. Skin Health Dis. 2021;1(4):e61. 10.1002/ski2.61 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Win Myint TT, Selak V, Elwood M. The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand). Skin Health Dis. 2022:e116. 10.1002/ski2.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ramirez‐Fort MK, Meier‐Schiesser B, Lachance K, Mahase SS, Church CD, Niaz MJ, et al. Folatehydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma. Skin Health Dis. 2021;1:e9. 10.1002/ski2.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Goon P, Banfield C, Bello O, Levell NJ. Skin cancers in skin types IV–VI: does the Fitzpatrick scale give a false sense of security? Skin Health Dis. 2021;1(3):e40. 10.1002/ski2.40 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.


Articles from Skin Health and Disease are provided here courtesy of Wiley

RESOURCES